The Type and Impact of Evidence Review Group Exploratory Analyses in the NICE Single Technology Appraisal Process

被引:4
|
作者
Carroll, Christopher [1 ]
Kaltenthaler, Eva [1 ]
Hill-McManus, Daniel [2 ]
Scope, Alison [1 ]
Holmes, Michael [1 ]
Rice, Stephen [3 ]
Rose, Micah [4 ]
Tappenden, Paul [1 ]
Woolacott, Nerys [5 ]
机构
[1] Univ Sheffield, Sheffield, S Yorkshire, England
[2] Bangor Univ, Bangor, Gwynedd, Wales
[3] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England
[4] Univ Southampton, Southampton, Hants, England
[5] Univ York, York, N Yorkshire, England
关键词
evidence review groups (ERGS); health policy; National Institute for Health and Care Excellence (NICE); single technology appraisal (STA); HEALTH; SUBMISSIONS;
D O I
10.1016/j.jval.2016.08.729
中图分类号
F [经济];
学科分类号
02 ;
摘要
Background: As part of the UK National Institute for Health and Care Excellence (NICE) single technology appraisal process, independent evidence review groups (ERGS) critically appraise a company's submission relating to a specific technology and indication. Objectives: To explore the type of additional exploratory analyses conducted by ERGS and their impact on the recommendations made by NICE. Methods: The 100 most recently completed single technology appraisals with published guidance were selected for inclusion. A content analysis of relevant documents was undertaken to identify and extract relevant data, and narrative synthesis was used to rationalize and present these data. Results: The types of exploratory analysis conducted in relation to companies' models were fixing errors, addressing violations, addressing matters of judgment, and the provision of a new, ERG-preferred base case. Ninety-three of the 100 ERG reports contained at least one of these analyses. The most frequently reported type of analysis in these 93 ERG reports related to the category "Matters of judgment," which was reported in 83 reports (89%). At least one of the exploratory analyses conducted and reported by an ERG is mentioned in 97% of NICE appraisal consultation documents and 94% of NICE final appraisal determinations, and had a clear influence on recommendations in 72% of appraisal consultation documents and 47% of final appraisal determinations. Conclusions: These results suggest that the additional analyses undertaken by ERGS in the appraisal of company submissions are highly influential in the policy-making and decision making process.
引用
收藏
页码:785 / 791
页数:7
相关论文
共 50 条
  • [1] ISSUES RELATED TO THE FREQUENCY OF EXPLORATORY ANALYSES BY EVIDENCE REVIEW GROUPS IN THE NICE SINGLE TECHNOLOGY APPRAISAL PROCESS
    Kaltenthaler, E.
    Carroll, C.
    Hill-McManus, D.
    Scope, A.
    Holmes, M.
    Rice, S.
    Rose, M.
    Tappenden, P.
    Woolacott, N.
    VALUE IN HEALTH, 2016, 19 (07) : A490 - A490
  • [2] Issues Related to the Frequency of Exploratory Analyses by Evidence Review Groups in the NICE Single Technology Appraisal Process
    Kaltenthaler E.
    Carroll C.
    Hill-McManus D.
    Scope A.
    Holmes M.
    Rice S.
    Rose M.
    Tappenden P.
    Woolacott N.
    PharmacoEconomics - Open, 2017, 1 (2) : 99 - 108
  • [3] THE ROLE AND IMPACT OF EVIDENCE REVIEW GROUP ANALYSES IN THE NICE SINGLE TECHNOLOGY ASSESSMENT (STA) PROCESS
    Carroll, C.
    Kaltenthaler, E.
    Tappenden, P.
    Hill-McManus, D.
    Scope, A.
    Holmes, M.
    Rice, S.
    Rose, M.
    Woolacott, N.
    VALUE IN HEALTH, 2016, 19 (07) : A468 - A469
  • [4] Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Ben Wijnen
    Willem Witlox
    Robert Wolff
    Debra Fayter
    Bram Ramaekers
    Thomas Otten
    Steve Ryder
    Pawel Posadzki
    Gill Worthy
    Lisa Stirk
    Nigel Armstrong
    Jos Kleijnen
    Manuela Joore
    PharmacoEconomics, 2023, 41 : 33 - 42
  • [5] Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
    Micah Rose
    Jonathan Shepherd
    Petra Harris
    Karen Pickett
    Joanne Lord
    PharmacoEconomics, 2018, 36 : 1299 - 1308
  • [6] Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Wijnen, Ben
    Witlox, Willem
    Wolff, Robert
    Fayter, Debra
    Ramaekers, Bram
    Otten, Thomas
    Ryder, Steve
    Posadzki, Pawel
    Worthy, Gill
    Stirk, Lisa
    Armstrong, Nigel
    Kleijnen, Jos
    Joore, Manuela
    PHARMACOECONOMICS, 2023, 41 (01) : 33 - 42
  • [7] Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Nigel Fleeman
    James Mahon
    Sarah Nevitt
    Rui Duarte
    Angela Boland
    Eleanor Kotas
    Yenal Dundar
    Joanne McEntee
    Sajjad Ahmad
    PharmacoEconomics - Open, 2019, 3 : 453 - 461
  • [8] Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
    Fleeman, Nigel
    Mahon, James
    Nevitt, Sarah
    Duarte, Rui
    Boland, Angela
    Kotas, Eleanor
    Dundar, Yenal
    McEntee, Joanne
    Ahmad, Sajjad
    PHARMACOECONOMICS-OPEN, 2019, 3 (04) : 453 - 461
  • [9] Etelcalcetide for Treating Secondary Hyperparathyroidism: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal
    Rose, Micah
    Shepherd, Jonathan
    Harris, Petra
    Pickett, Karen
    Lord, Joanne
    PHARMACOECONOMICS, 2018, 36 (11) : 1299 - 1308
  • [10] Ixazomib for Relapsed or Refractory Multiple Myeloma: Review from an Evidence Review Group on a NICE Single Technology Appraisal
    Armoiry, Xavier
    Connock, Martin
    Tsertsvadze, Alexander
    Cummins, Ewen
    Melendez-Torres, G. J.
    Royle, Pam
    Clarke, Aileen
    PHARMACOECONOMICS, 2018, 36 (09) : 1073 - 1081